Application note: Nitrosamines in drug product by HRAM-LCMS
Posted: 16 June 2020 | Thermo Fisher Scientific | No comments yet
HPLC with HRAM MS method for the determination and quantitation of nitrosamine impurities in drug products consistent with FDA requirements.
This application note details a simple, fast method using HRAM LCMS consistent with current FDA recommendations, for the quantitative analysis of common nitrosamines in drug product formulations and drug substances.
Application benefits:
- 11 nitrosamines
- Confidence in HRAM confirmation of impurities
- Quantitation of nitrosamines in drug substance and product samples in line regulatory guidelines
- Acquisition to reporting in GMP compliance-ready software with data integrity and 21CFR11 toolset
Related content from this organisation
- Whitepaper: Drug repurposing trends and strategic approaches for shortening timelines
- Implementing the FAIR data principles is now a critical endeavour
- The role of digital transformation in achieving Pharma 4.0
- How COVID-19 has accelerated digital transformation and how laboratory orchestration platforms are changing the landscape
- Enabling compliant data management with a comprehensive informatics solution
Related topics
Analytical techniques, Biopharmaceuticals, Chromatography, Data integrity, Excipients, Formulation, Good Manufacturing Practice (GMP), Manufacturing, Mass Spectrometry, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D)
